Richard DiMarchi, a faculty member at Indiana University Bloomington, has played a central role in the development of peptide-based drugs that have changed the treatment of obesity and diabetes. DiMarchi’s career includes time at Eli Lilly and Company, where he contributed to the discovery of chemically optimized human insulin. His work at IU focused on GLP-1 and other peptide hormones, helping to shift scientific understanding toward treating obesity as a disease rather than an issue of willpower.
Approximately 700,000 adults in Indiana are affected by diabetes, and about one-third face obesity. DiMarchi’s research has led to new pharmaceutical options for these conditions. While working as group vice president at Lilly, he helped create rDNA-derived medicines for diabetes. Through further study with colleagues, they found that these drugs also supported weight loss.
James Andry, a physician specializing in weight loss in Bloomington, said: “No one wanted to touch pharmaceutical solutions for obesity in the 1990s, even though it is just as much a disease as diabetes or high blood pressure. And now Indiana has become a center of not just the thought but also the manufacture of medications that are proving to be some of the most life-changing medical treatments we’ve ever seen.”
Indiana University Bloomington has been home to several major discoveries in chemistry beyond DiMarchi’s contributions. These include innovations such as Crest toothpaste’s key ingredient and recent advances by professors Amar Flood and Martin Jarrold in materials science and mass spectrometry.
Andry highlighted DiMarchi’s approach: “The most brilliant thing you can do isn’t necessarily develop new things; it’s to notice new things. DiMarchi noticed that you could make this small change in just a couple of amino acids on insulin and make it work better as a medicine. That’s the scientific story.”
DiMarchi began his academic journey with degrees from Florida Atlantic University and Indiana University before post-doctoral work at Rockefeller University under Nobel laureate Bruce Merrifield. At Lilly, he demonstrated that synthetically optimized peptides could be more effective than natural hormones.
David Clemmer, IU Distinguished Professor of Chemistry, said: “Richard is not a typical faculty member. He’s singularly gifted, and able to manage worlds outside of his world. He could easily retire tomorrow but he doesn’t because he wants to make people healthier.” Clemmer added: “Innovation is not easy to come by in industry because everybody’s so focused on stock prices. That fundamental research — research like the kind Richard DiMarchi conducts — has to come from laboratories at universities, smaller companies and startups.”
DiMarchi insisted on joining IU’s Department of Chemistry due to its reputation: “at the core I am a chemist, and the chemistry department at Indiana University Bloomington is world-class.” Clemmer noted that collaboration with researchers like Matthias Tschöp was another draw for DiMarchi: “What that means is that you can just get things done here,” Clemmer said.
Currently holding the Linda and Jack Gill Chair in Biomolecular Science within IU’s College of Arts and Sciences, DiMarchi sees academia as crucial for innovation: academia “is a place for people who are iconoclastic, for people who want to create the future.”
He holds over 100 U.S. patents and founded eight biotechnology start-ups. His achievements include induction into the National Inventors Hall of Fame for synthetic insulin development; receiving the Mani L. Bhaumik Breakthrough of the Year Award (2024) for GLP-1/obesity research; and sharing with Tschöp the 2026 Rolf Luft Award.
Despite these accolades, DiMarchi considers mentoring students his most important contribution: “The biggest reward is the people you produce,” he said. “I’ve contributed technology and drug candidates to the world, but I’ve also contributed the next generation of scientists capable of continuing to improve the world.”
Former students hold leadership roles across academia and industry—such as vice president positions at Lilly or deanships at Columbia State University—and many remain active contributors within Indiana biosciences.
John Mayer credited his own success leading peptide research groups at Lilly directly to DiMarchi’s mentorship: “I would not have had the career I had without his mentorship,” Mayer said. “Richard brings incredible passion and drive for science…”
Archita Agrawal reflected on her training under DiMarchi while working now with Salk Institute scientist Alan Saghatelian: “He coached me to value that science demands integrity… He also taught me that you can’t give up when you fail in science because there’s going to be a lot of failures.”
DiMarchi summed up biotechnology’s impact beyond weight control alone: “We’re not just controlling weight,” he said. “By treating obesity, we may also be improving cognition, preventing cancer and lengthening our lives… universities — Indiana University certainly being one of them — have…the obligation to use these powers to create products and people that make a real difference.”
Indiana University Bloomington serves as both an educational institution drawing students from all 50 states plus over 150 countries [source] and as an economic contributor with historic limestone architecture [source]. The university functions as a public research institution dedicated to advancing creativity and innovation [source], playing an ongoing role in scientific discovery statewide.
